JP6271700B2 - ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体 - Google Patents

ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体 Download PDF

Info

Publication number
JP6271700B2
JP6271700B2 JP2016501072A JP2016501072A JP6271700B2 JP 6271700 B2 JP6271700 B2 JP 6271700B2 JP 2016501072 A JP2016501072 A JP 2016501072A JP 2016501072 A JP2016501072 A JP 2016501072A JP 6271700 B2 JP6271700 B2 JP 6271700B2
Authority
JP
Japan
Prior art keywords
triazol
compound
mmol
isoquinolin
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016501072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512515A5 (enExample
JP2016512515A (ja
Inventor
デイヴィッド ローソン、ジョン
デイヴィッド ローソン、ジョン
サバト、マーク
スコラー、ニコラス
スミス、クリストファー
エイチ． ヴー、フォン
エイチ． ヴー、フォン
ワン、ハイシャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2016512515A publication Critical patent/JP2016512515A/ja
Publication of JP2016512515A5 publication Critical patent/JP2016512515A5/ja
Application granted granted Critical
Publication of JP6271700B2 publication Critical patent/JP6271700B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016501072A 2013-03-11 2014-03-10 ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体 Active JP6271700B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361776445P 2013-03-11 2013-03-11
US61/776,445 2013-03-11
PCT/US2014/022801 WO2014164558A1 (en) 2013-03-11 2014-03-10 Pyridinyl and fused pyridinyl triazolone derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017252294A Division JP6462842B2 (ja) 2013-03-11 2017-12-27 ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体

Publications (3)

Publication Number Publication Date
JP2016512515A JP2016512515A (ja) 2016-04-28
JP2016512515A5 JP2016512515A5 (enExample) 2017-04-13
JP6271700B2 true JP6271700B2 (ja) 2018-01-31

Family

ID=50543655

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501072A Active JP6271700B2 (ja) 2013-03-11 2014-03-10 ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体
JP2017252294A Active JP6462842B2 (ja) 2013-03-11 2017-12-27 ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017252294A Active JP6462842B2 (ja) 2013-03-11 2017-12-27 ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体

Country Status (43)

Country Link
US (4) US9402841B2 (enExample)
EP (2) EP2970202B1 (enExample)
JP (2) JP6271700B2 (enExample)
KR (1) KR102300612B1 (enExample)
CN (1) CN105121427B (enExample)
AP (1) AP2015008646A0 (enExample)
AR (1) AR095198A1 (enExample)
AU (1) AU2014249248B2 (enExample)
BR (1) BR112015020264B1 (enExample)
CA (1) CA2899948C (enExample)
CL (1) CL2015002370A1 (enExample)
CR (1) CR20150470A (enExample)
CY (1) CY1119356T1 (enExample)
DK (1) DK2970202T3 (enExample)
DO (1) DOP2015000184A (enExample)
EA (1) EA028584B1 (enExample)
EC (1) ECSP15042779A (enExample)
ES (2) ES2624439T3 (enExample)
GE (1) GEP201706778B (enExample)
HK (1) HK1245256B (enExample)
HR (1) HRP20170622T1 (enExample)
HU (1) HUE032720T2 (enExample)
IL (1) IL240353B (enExample)
JO (1) JO3377B1 (enExample)
LT (1) LT2970202T (enExample)
MA (1) MA38391B1 (enExample)
ME (1) ME02693B (enExample)
MX (1) MX364527B (enExample)
MY (1) MY183927A (enExample)
PE (1) PE20151889A1 (enExample)
PH (1) PH12015502046B1 (enExample)
PL (1) PL2970202T3 (enExample)
PT (1) PT2970202T (enExample)
RS (1) RS55879B1 (enExample)
SG (1) SG11201506112QA (enExample)
SI (1) SI2970202T1 (enExample)
SM (1) SMT201700218T1 (enExample)
TN (1) TN2015000342A1 (enExample)
TW (1) TWI637950B (enExample)
UA (1) UA114944C2 (enExample)
UY (1) UY35376A (enExample)
WO (1) WO2014164558A1 (enExample)
ZA (1) ZA201505996B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018076357A (ja) * 2013-03-11 2018-05-17 武田薬品工業株式会社 ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900344T1 (it) 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
CN104447530A (zh) * 2014-12-11 2015-03-25 苏州欧凯医药技术有限公司 4-甲基-2,6-二羧基吡啶的制备方法
SG11201704808VA (en) * 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2017111179A1 (en) 2015-12-24 2017-06-29 Takeda Pharmaceutical Company Limited Cocrystal, production method thereof, and medicament containing cocrystal
EP3402503B1 (en) * 2016-01-13 2020-10-21 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
JP7305352B2 (ja) * 2016-03-31 2023-07-10 武田薬品工業株式会社 イソキノリニルトリアゾロン錯体
IL263815B (en) 2016-06-29 2022-07-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP7682541B2 (ja) * 2019-04-02 2025-05-26 延世大学校 産学協力団 新規化合物およびこれを有効成分として含む呼吸器疾患の予防または治療用組成物
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
AU2020365951B2 (en) 2019-10-14 2026-07-16 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
KR102993352B1 (ko) 2019-12-20 2026-07-22 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
UY39377A (es) 2020-08-14 2022-03-31 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN122295111A (zh) * 2023-11-30 2026-06-26 吉恩特药业株式会社 用于治疗自身免疫病的组合物和方法
WO2026133229A1 (en) 2024-12-20 2026-06-25 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5733849A (en) * 1996-03-15 1998-03-31 Rohm And Haas Company Halopyridyl triazolinone herbicides and herbicidal use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU3653099A (en) 1998-04-17 1999-11-08 Parker Hughes Institute Btk inhibitors and methods for their identification and use
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
JP5441691B2 (ja) * 2006-05-25 2014-03-12 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
MX2008015843A (es) 2006-06-20 2009-01-09 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos.
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2229390B1 (en) 2007-12-14 2014-04-09 F. Hoffmann-La Roche AG Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives
ES2420846T3 (es) 2008-02-05 2013-08-27 F. Hoffmann-La Roche Ag Nuevas piridinonas y piridazinonas
PE20100851A1 (es) 2008-06-24 2011-01-31 Hoffmann La Roche PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
PL2300459T3 (pl) 2008-07-02 2013-10-31 Hoffmann La Roche Nowe fenylopirazynony jako inhibitory kinazy
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
CA2815131C (en) 2010-10-20 2020-06-09 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as kcnq2/3 modulators
EP2637816A4 (en) 2010-11-10 2017-07-26 Stc.Unm Aerosol reduction/expansion synthesis (a-res) for zero valent metal particles
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018076357A (ja) * 2013-03-11 2018-05-17 武田薬品工業株式会社 ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体

Also Published As

Publication number Publication date
NZ710852A (en) 2020-12-18
SG11201506112QA (en) 2015-09-29
TWI637950B (zh) 2018-10-11
PH12015502046B1 (en) 2019-01-23
AP2015008646A0 (en) 2015-08-31
MX364527B (es) 2019-04-30
ES2714166T3 (es) 2019-05-27
AR095198A1 (es) 2015-09-30
HUE032720T2 (en) 2017-10-30
CN105121427B (zh) 2018-04-10
JP2018076357A (ja) 2018-05-17
EP3235814B1 (en) 2018-12-12
GEP201706778B (en) 2017-11-27
JP6462842B2 (ja) 2019-01-30
HK1220183A1 (en) 2017-04-28
PL2970202T3 (pl) 2017-08-31
LT2970202T (lt) 2017-06-12
AU2014249248A1 (en) 2015-08-20
EA201591686A1 (ru) 2015-12-30
JP2016512515A (ja) 2016-04-28
KR102300612B1 (ko) 2021-09-09
US9801872B2 (en) 2017-10-31
PT2970202T (pt) 2017-05-03
TW201522328A (zh) 2015-06-16
CR20150470A (es) 2016-01-11
DOP2015000184A (es) 2015-11-30
IL240353B (en) 2018-11-29
MA38391B1 (fr) 2018-09-28
ME02693B (me) 2017-10-20
SMT201700218T1 (it) 2017-07-18
IL240353A0 (en) 2015-09-24
BR112015020264A2 (pt) 2017-07-18
TN2015000342A1 (en) 2017-01-03
EA028584B1 (ru) 2017-12-29
EP2970202A1 (en) 2016-01-20
UA114944C2 (uk) 2017-08-28
WO2014164558A1 (en) 2014-10-09
US20190224190A1 (en) 2019-07-25
DK2970202T3 (en) 2017-05-08
CN105121427A (zh) 2015-12-02
CA2899948A1 (en) 2014-10-09
HK1245256B (en) 2019-09-27
US20140256734A1 (en) 2014-09-11
US20180015083A1 (en) 2018-01-18
MX2015011533A (es) 2016-02-03
MY183927A (en) 2021-03-17
US20160310483A1 (en) 2016-10-27
ES2624439T3 (es) 2017-07-14
KR20150126687A (ko) 2015-11-12
HRP20170622T1 (hr) 2017-06-30
AU2014249248B2 (en) 2017-08-17
CL2015002370A1 (es) 2016-03-11
ECSP15042779A (es) 2017-08-31
ZA201505996B (en) 2016-11-30
EP3235814A1 (en) 2017-10-25
PH12015502046A1 (en) 2016-01-18
CY1119356T1 (el) 2018-02-14
US9402841B2 (en) 2016-08-02
JO3377B1 (ar) 2019-03-13
PE20151889A1 (es) 2015-12-26
MA38391A1 (fr) 2018-01-31
EP2970202B1 (en) 2017-02-01
BR112015020264B1 (pt) 2021-03-02
RS55879B1 (sr) 2017-08-31
SI2970202T1 (sl) 2017-07-31
UY35376A (es) 2014-10-31
CA2899948C (en) 2021-11-16
US10307414B2 (en) 2019-06-04

Similar Documents

Publication Publication Date Title
JP6462842B2 (ja) ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体
HK1245256A1 (en) Pyridinyl and fused pyridinyl triazolone derivatives
JP6196710B2 (ja) Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン
EP2723739B1 (en) Substituted 6-aza-isoindolin-1-one derivatives
HK1220183B (en) Pyridinyl and fused pyridinyl triazolone derivatives
HK40051882A (en) Fused heteroaromatic pyrrolidinones as syk inhibitors
NZ710852B2 (en) Pyridinyl and fused pyridinyl triazolone derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171227

R150 Certificate of patent or registration of utility model

Ref document number: 6271700

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250